Antheia Closes Expanded Series C to Scale U.S. Manufacturing and Commercialization Pipeline

New updates have been reported about Antheia.

Antheia has completed a second close of its Series C round, adding $24 million in new capital and bringing its total capital secured over the past year to more than $175 million, including additional available capital and non-dilutive funding tied to multiple U.S. government project agreements. The company plans to deploy the proceeds to expand commercial manufacturing capacity for its advanced biosynthesis platform, accelerate market entry for a broad pipeline of late-stage biosynthetic pharmaceutical ingredients, and establish U.S.-based manufacturing operations aligned with federal onshoring and supply-chain security priorities. CEO and co-founder Dr. Christina Smolke said the additional funding will support Antheia’s efforts to address critical pharmaceutical supply chain vulnerabilities and drive a structural shift in how medicines are manufactured.

The second close was led by ATHOS KG and America’s Frontier Fund, with participation from existing investors including Global Health Investment Corporation, which co-led the initial Series C close with EDBI. America’s Frontier Fund characterized Antheia as a strategic asset for U.S. industrial leadership, highlighting its potential to mitigate shortages, long lead times, and geopolitical risks by combining advanced biosynthesis with scalable domestic production. The fresh capital follows a series of operational milestones in 2024–2025, including Antheia’s first commercial delivery of thebaine, a key input for Narcan, and two U.S. government agreements aimed at onshoring critical pharmaceutical supply chains, as well as a strategic commercialization partnership with TAPI. Collectively, the funding, government backing, and commercial traction position Antheia as a key player in reshaping resilient, efficient supply of essential pharmaceutical ingredients and enabling future therapeutic innovation.